Outlook Therapeutics, Inc. (NASDAQ:OTLK) Receives Consensus Recommendation of "Buy" from Brokerages

Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK - Get Free Report) have been given an average rating of "Buy" by the seven ratings firms that are presently covering the company, Marketbeat.com reports. Seven analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have covered the stock in the last year is $48.20.

• 3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices

Several research analysts recently commented on the company. Ascendiant Capital Markets cut their price target on Outlook Therapeutics from $35.00 to $33.00 and set a "buy" rating on the stock in a research note on Tuesday, September 3rd. HC Wainwright reaffirmed a "buy" rating and issued a $30.00 target price on shares of Outlook Therapeutics in a research report on Thursday, August 15th. Chardan Capital reissued a "buy" rating and set a $53.00 price target on shares of Outlook Therapeutics in a research report on Friday, August 16th. Finally, BTIG Research reaffirmed a "buy" rating and issued a $50.00 price target on shares of Outlook Therapeutics in a report on Friday, October 18th.

Check Out Our Latest Stock Analysis on Outlook Therapeutics

Outlook Therapeutics Price Performance

• MarketBeat Week in Review – 6/17 - 6/21

Shares of NASDAQ OTLK opened at $5.74 on Wednesday. The company has a market capitalization of $135.79 million, a price-to-earnings ratio of -0.50 and a beta of 0.62. Outlook Therapeutics has a 1-year low of $4.61 and a 1-year high of $13.32. The business has a 50-day moving average of $6.16 and a 200-day moving average of $7.21.

Outlook Therapeutics (NASDAQ:OTLK - Get Free Report) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.06) by $0.23. Research analysts expect that Outlook Therapeutics will post -3.63 EPS for the current fiscal year.

Insider Buying and Selling at Outlook Therapeutics

• Outlook Therapeutics: Analysts Forecast Over 500% Stock Upside

In other Outlook Therapeutics news, CFO Lawrence A. Kenyon acquired 5,000 shares of the stock in a transaction that occurred on Thursday, September 26th. The stock was acquired at an average price of $5.69 per share, with a total value of $28,450.00. Following the transaction, the chief financial officer now directly owns 5,946 shares in the company, valued at approximately $33,832.74. This represents a 500.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 3.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Outlook Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Great Point Partners LLC increased its holdings in shares of Outlook Therapeutics by 15.0% in the 2nd quarter. Great Point Partners LLC now owns 1,701,510 shares of the company's stock worth $12,557,000 after acquiring an additional 221,510 shares during the period. Susquehanna Fundamental Investments LLC acquired a new stake in shares of Outlook Therapeutics in the second quarter valued at approximately $303,000. Squarepoint Ops LLC bought a new stake in shares of Outlook Therapeutics during the second quarter valued at approximately $232,000. Christensen King & Associates Investment Services Inc. acquired a new position in shares of Outlook Therapeutics during the third quarter worth approximately $55,000. Finally, AQR Capital Management LLC bought a new position in Outlook Therapeutics in the 2nd quarter worth approximately $75,000. 11.20% of the stock is owned by institutional investors and hedge funds.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.

Featured Stories

• Five stocks we like better than Outlook Therapeutics
• What Are Dividend Contenders? Investing in Dividend Contenders
• Is McDonald's Stock a Smart Buy After Sell-Off and Earnings?
• Why is the Ex-Dividend Date Significant to Investors?
• QuantumScape: Solid State EV Batteries Nearing Commercialization
• What Investors Need to Know About Upcoming IPOs
• MicroStrategy: Is This Bitcoin-Powered Stock a Buy or a Gamble?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

→ The real reason Elon is fully endorsing Trump (From Porter & Company) (Ad)

Should you invest $1,000 in Outlook Therapeutics right now?

Before you consider Outlook Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Outlook Therapeutics wasn't on the list.

While Outlook Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here